Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Abstract Background Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and diseas...
Main Authors: | Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D’Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo, Emilio Hirsch, Alessia Ciarrocchi, Giorgio Inghirami, Antonino Neri, Roberto Piva |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40164-023-00434-x |
Similar Items
-
Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
by: Elisabetta Mereu, et al.
Published: (2023-04-01) -
Machine-Learning-Enabled Virtual Screening for Inhibitors of Lysine-Specific Histone Demethylase 1
by: Jiajun Zhou, et al.
Published: (2021-12-01) -
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases
by: Hideaki Niwa, et al.
Published: (2017-05-01) -
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
by: Tina Paradzik, et al.
Published: (2021-03-01) -
Crucial Role of Lysine-Specific Histone Demethylase 1 in RANKL-Mediated Osteoclast Differentiation
by: Mina Ding, et al.
Published: (2023-02-01)